US: PuriCore Q3 Interim Management Statement

PuriCore , the life sciences company focused on developing and
commercializing proprietary, green solutions that safely, effectively, and
naturally kill infectious pathogens without causing harm to human health or the
environment, today issues an Interim Management Statement covering the
three-month and nine-month periods ending September 30, 2009.

Financial Results (unaudited)

* Q3 sales of $10.6 million (2008: $8.4 million), an increase of 25% (35%
increase at constant currency)

* US Food Safety revenue increased 10% to $5.8 million
* UK Endoscopy (including Sterilox business and Labcaire Systems) revenue
increased 52% to $4.6 million (78% at constant currency); Labcaire Systems
revenue for the period 5 August to 30 September 2009 totaled $2.5 million

* Sales for the nine months ending September 30 of $29.6 million (2008: $27.9
million), an increase of 6% (17% increase at constant currency)

* US Food Safety revenue increased 14% to $18.5 million
* UK Endoscopy revenue decreased by 5% to $10.8 million (20% increase at
constant currency)

* Cash of $8.4 million at period end

Q3 Operational Highlights

* Completed the acquisition of Labcaire Systems Ltd., a leading UK supplier and
manufacturer of endoscope disinfection equipment, which is performing ahead of
internal expectations
* Raised £2 million by way of a Placing through the issue of 10,810,811 Placing
Shares at an Issue Price of 18.5 pence per share to fund the upfront payment for
the Labcaire acquisition
* Established a new $2.1 million debt facility consistent with the Company`s
strategy to utilize debt to fund the installation of leased Sterilox Food Safety
Systems
* Received a new FDA 510(k) clearance for Vashe Wound Therapy extending
shelf-life claims

Post-Period Developments

* Signed major contracts with another top-10 US national supermarket chain and
another leading regional supermarket retailer for Sterilox Food Safety Systems
to be installed in 2010 totaling approximately $4.7 million in lease revenues
* Completed a randomized clinical trial on the effectiveness of Vashe Wound
Therapy on post-operative, split-thickness skin grafts for burn injuries with
positive clinical results expected to be presented in early November
* Promoted Darren Weiss to CFO and Executive Director effective November 1,
2009

Outlook

Results for Q3 2009 were strong despite the weakness of UK sterling (compared
with Q3 2008 and 30 September YTD 2008), driven by the growth in PuriCore`s US
Food Safety core business, with approximately 50 US supermarket chains using
Sterilox as at 30 September 2009, as well as by the incremental revenue achieved
by Labcaire for the UK Endoscopy core business, which exceeded internal
expectations. The Company remains on target with plans for the integration of
Labcaire into the PuriCore UK Endoscopy business and for continuing to control
operating expenses throughout the Company for the full year. PuriCore continues
to successfully shift the business toward a lease versus capital sales model and
expects this to continue in 2010.

Greg Bosch, Chief Executive Officer of PuriCore, said:

"The continued market adoption of our Sterilox Food Safety Systems is further
evidenced by the recent contract awards from two additional leading customers,
including another top-10 retailer. The acquisition of Labcaire positions
PuriCore as the leading provider of endoscope reprocessing products and services
for our UK customers with a broad portfolio, and we look to expand our marketing
of Labcaire products internationally in 2010."

About PuriCore

PuriCore plc is a life sciences company focused on developing and
commercializing proprietary green solutions that safely, effectively, and
naturally kill infectious pathogens without causing harm to human health or the
environment. PuriCore`s patented, proprietary technology mimics the human body`s
production of the natural antimicrobial hypochlorous acid, offering a safe and
non-hazardous approach to disinfection and sanitisation. The Company`s products
are used in a broad range of markets that depend upon controlling contamination,
including food retail and foodservice, medical device disinfection, and wound
care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast
acting against a broad range of infectious pathogens, including major public
health threats of C.difficile, E.coli, HIV, Human and Animal Influenza
(including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and
Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in
Stafford and Clevedon, UK.

Publication date: 11/6/2009

respond to this article  email this article    print

Receive the daily newsletter in your email for free | Click here

 

<< back | www.freshplaza.com